What's happening
Live detector signal
Generated 19:37 ET
GTBP — GT Biopharma Inc. Common Stock is up 36.7%, at 8.45, on $3.5M traded, 11.6× 20-day volume. Score 98. Primary driver: $3.5M traded. Supply intelligence: mixed supply · 60.
Get alerts on $GTBP
Halts, resumptions, new filings, and updated reports — in your inbox within minutes of the event.
Free · one email per event, no digests or spam · unsubscribe anytime · joins real followers
Free float
—, refreshing
2026-02-23
Shares out
1.8M
latest detail
Market cap
$11.2M
at ref price
Short interest
13.0%
2026-08-31
Float rotation
0.01×
latest snapshot
20d dollar vol
$225.9K
baseline
Gap quality
mixed supply · 60
live supply-pressure model
Supply factor
positive gap demand
detector reason
Supply factor
elevated short interest
detector reason
Supply factor
nano-cap supply profile
detector reason
Supply factor
recent reverse split dilution risk
detector reason
This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.
2026-09-11 14:55 ETSignalGT Biopharma Inc. Common Stock is up 36.7%, at 8.45, on $3.5M traded, 11.6× 20-day volume. Score 98. Primary driver: $3.5M traded. Supply intelligence: mixed supply · 60.
2026-09-08Split1-for-25 reverse split logged
2026-09-038-KItem 3.03 — Material modification to rights of security holders; Item 5.03 — Amendments to charter or bylaws +1 more SEC
2026-06-128-KItem 5.03 — Amendments to charter or bylaws; Item 9.01 — Financial statements and exhibits SEC
2026-06-02 09:02 ETFDA / ClinicalA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company News
2026-05-228-KItem 3.01 — Notice of delisting or failure to satisfy listing rule; Item 9.01 — Financial statements and exhibits SEC
2026-05-14 10:55 ETFDA / Clinical"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies News
2025-12-04 12:20 ETFDA / ClinicalBlood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points News
Latest detector signalscore 98